The Indian pharma market grew 5.1 per cent year on year in September, led by cardiac, dermal and anti-diabetic therapies, a report showed on Monday.
The industry grew 7.7 per cent year on year in the 12 months ending in September, led by price growth and new launches. However, volume growth was moderate at 0.8 per cent on-year last month, according to the report by Motilal Oswal Financial Services Ltd.
Acute therapies growth continued to stay moderate at 3 per cent YoY, while chronic therapies growth was 8 per cent last month.
Acute therapies segment constituted 61.3 per cent of the overall Indian pharma market in terms of moving annual total, with 3 per cent YoY growth, while the chronic therapies constituted 38.7 per cent of the total industry, which grew by 8 per cent, the report added.
Indian pharma companies had dominated the market with 84 per cent market share whereas the balance was held by Multinational pharma companies.
According to report, MNCs as well as Indian companies had achieved single digit growth (on-quarter) last month.
Augmentin, the industry's top brand suffered a decline of 2% YoY to Rs 730 mln with 0.4 per cent market share last month.
Companies that had 16.5 per cent and 10.2 per cent YoY growth in September were the ones who topped the league with Rs 569 mn and Rs 572 mn from sales of Udiliv and Thyronorm, respectively.
While the firms continue to cash in one-off opportunities over FY25-26, the report at BNP Paribas said, "the key would be ready a product pipeline for launch beyond FY26.".
Some firms are investing in biosimilars, but we think Indian firms may be late entrants and might not get the traction they expect," the report mentioned.
Read also| Sensex Rises 591 Points, Realty and Banking Stocks Lead the Surge
Read also| Indian Markets Outperform China in Returns Over the Last 5 Years, Sebi Member
